VIVUS cut QSIVA prices in Nordic nations and Poland to boost patient access to the cardiovascular drug.

VIVUS has announced a price reduction for its QSIVA® medication across the Nordic countries and Poland, effective immediately. The move aims to improve patient access to the treatment, which is used for certain cardiovascular conditions. The company did not disclose specific pricing details but emphasized the reduction supports broader healthcare affordability in the region.